Recognizing the Disruptive Potential of Cancer Immunotherapy

This article from MDB Communications discusses ten cancer vaccine programs in mid- and late-stage development with important catalysts expected during the balance of 2013 and into 2014. The article also highlights how several of these newer products seem to work better and address the

Rethinking Immunotherapy for Brain Tumors

Eight companies with immunotherapy approaches for brain tumors

Adjuvants May Hold Key to Unlocking Cancer Immunotherapy Revolution

Often overlooked, adjuvants can be an essential part of an effective vaccine and could help advance the field of cancer immunotherapy even further.

Similarities Between Two Immunotherapies in Cancer

Approval of Bristol-Myers Squibb’s Yervoy® [ipilimumab] for melanoma in March 2011 marked the second victory for the field of immunotherapy in oncology within a year.

Ipilimumab Approval Highlights Immunotherapy Renaissance

On March 25, 2011, Yervoy® [ipilimumab] by Bristol-Myers Squibb became the eleventh mAb approved by the FDA for the treatment of cancer.

Five Key Factors Weighing on Dendreon

Shares of Dendreon Corporation (DNDN) have declined significantly from an all-time high of $57.67 in late April 2010 when the company received U.S. Food and Drug Administration [FDA] approval for Provenge® [sipuleucel-T], the first active immunotherapy approved for the treatment of ca

Cancer Immunotherapy to Take Center Stage at ASCO

In early April 2010, we published a 150-page industry report titled “Cancer Vaccine Therapies: Failures and Future Opportunities,” which included an overview of the cancer immunotherapy market, interviews with several key opinion leaders, profiles of nearly 40 companies, and a discuss